HCPLive

Despite Combined Antiretroviral Treatment, Anal Cancer Risk Still High for HIV-Infected

 
THURSDAY, Dec. 13 (HealthDay News) -- For HIV-infected patients, despite combined antiretroviral treatment (cART), the risk of anal cancer is still much higher than in the general population, according to a study published in the Dec. 10 issue of the Journal of Clinical Oncology.

Christophe Piketty, M.D., Ph.D., from the Hôpital Européen Georges Pompidou in Paris, and colleagues compared the incidence rates of anal cancer across four time periods: 1992 to 1996 (pre-cART); 1997 to 2000 (early cART); and 2001 to 2004 and 2005 to 2008 (both recent cART). During these periods, 263 cases of histologically confirmed invasive anal squamous cell carcinoma were identified.

The researchers found that, for HIV-infected patients, the hazard ratio for anal cancer was 2.5 in the cART periods versus the pre-cART period, with no difference noted across the cART calendar periods. In 2005 to 2008, compared with the general population, for HIV-infected patients there was an excess risk of anal cancer with a standardized incidence ratio of 109.8 for men who have sex with men (MSM), 49.2 for other men, and 13.1 for women. For patients with CD4 counts above 500/µL for at least two years, the standardized incidence ratios were 67.5 and 24.5, respectively, when the CD4 nadir was less than 200/µL for more than two years or more than 200/µL.

"Relative to that in the general population, the risk of anal cancer in HIV-infected patients is still extremely high, even in patients with high current CD4 cell counts," the authors write. "cART appears to have no preventive effect on anal cancer, particularly in MSM."
 

Abstract
Full Text (subscription or payment may be required)

 
Copyright © 2012 HealthDay. All rights reserved.
 

Most Popular

Recommended Reading

The field of medical technology is constantly expanding and changing requiring new equipment to be used in a variety of ways. That effort has been brought under one roof at Massachusetts General Hospital thanks in part to the efforts of one generous and appreciative patient.
Intraperitoneal (IP) chemotherapy offers lasting benefit for patients with advanced ovarian cancer, according to a study published online March 23 in the Journal of Clinical Oncology.

Burnout can be prevented if physicians are aware of the warning signs, according to an article published by the American Medical Association.

Novel treatments for pulmonary conditions, such as asthma and chronic obstructive pulmonary disease (COPD), may be in the cards with new research findings.
$vAR$